Publications

Targeting Transcription-Replication Conflicts using G-quadruplexes stabilizers in Multiple Myeloma.

Epigenome modifications and genomic instability in normal and malignant B cells

+ Maintenance of genome integrity during DNA replication

Laure DUTRIEUX, Sara OVEJERO, Antoine GUILLEMIN, Miss Leriem ZELLAGUI, Elke De BRUYNE, Catharina MUYLAERT, Lien VAN HEMELRIJCK, Yea-Lih LIN, Elle LOUGHRAN, Armelle CHOQUET, Talha MAGAT, Soumya BOUCHOUIKA, Caroline BRET, Guilhem REQUIRAND, Nicolas ROBERT, Laure VINCENT, Guillaume CARTRON, Charles HERBAUX, Raphaël RODRIGUEZ, Michel COGNE, Eric RIVALS, Jean-Christophe ANDRAU, Alexandre DAVID, Philippe PASERO, and Jérôme MOREAUX

Tubulin detyrosination shapes Leishmania cytoskeletal architecture and virulence.

Tubulin code

Corrales RM, Vincent J, Crobu L, Neish R, Nepal B, Espeut J, Pasquier G, Gillard G, Cazevieille C, Mottram JC, Wetzel DM, Sterkers Y, Rogowski K, Lévêque MF

TPR is required for cytoplasmic chromatin fragment formation during senescence

Nuclear architecture in physiology and pathology

Bethany M Bartlett, Yatendra Kumar, Shelagh Boyle, Tamoghna Chowdhury, Andrea Quintanilla, Charlene Boumendil, Juan Carlos Acosta, Wendy A Bickmore

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Epigenome modifications and genomic instability in normal and malignant B cells

Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Epigenome modifications and genomic instability in normal and malignant B cells

Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V, on the behalf of the FILO group

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Epigenome modifications and genomic instability in normal and malignant B cells

Arribas AJ, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, Bordone-Pittau R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F

piRNAs are regulators of metabolic reprogramming in stem cells

mRNA Regulation and Development

Rojas-Ríos P, Chartier A, Enjolras C, Cremaschi J, Garret C, Boughlita A, Ramat A, Simonelig M

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.

Epigenome modifications and genomic instability in normal and malignant B cells

Lenz G, Tilly H, Ziepert M, Altmann B, Herbaux C, Frontzek F, Nickelsen M, Lee C, Hirata J, Sahin D, Chohan S, Batlevi CL, Yan M, Morschhauser F, Schmitz N